ZIOPHARM Oncology, Inc. (ZIOP) Stock Analysis

ZIOPHARM Oncology, Inc. (ZIOP) Healthcare & Pipeline Overview

ZIOPHARM Oncology, Inc. pioneers immuno-oncology therapies, leveraging its Sleeping Beauty platform and Controlled IL-12 technology to engineer T-cells and stimulate the immune system against cancer. The company focuses on solid tumors and hematologic malignancies, operating in the competitive biotechnology sector.

What Is the Investment Thesis for ZIOP?

ZIOPHARM Oncology, Inc. presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The company's innovative Sleeping Beauty and Controlled IL-12 platforms offer potential for breakthrough cancer therapies. Key value drivers include successful clinical trial outcomes for its lead product candidates, particularly Ad-RTS-hIL-12 plus veledimex for recurrent glioblastoma multiforme. Upcoming clinical data releases throughout 2026 will be critical in validating the efficacy and safety of these therapies. However, the company's significant negative profit margin of -83520.0% and gross margin of -3600.0% highlight the substantial financial challenges. The company's success hinges on securing regulatory approvals and establishing commercial partnerships. The high beta of 1.69 indicates significant volatility, reflecting the speculative nature of clinical-stage biopharmaceutical investments.

Based on FMP financials and quantitative analysis

ZIOP Key Highlights

Market capitalization of $0.21 billion reflects investor sentiment regarding ZIOPHARM's pipeline and potential.

• Negative profit margin of -83520.0% indicates substantial ongoing research and development expenses.
• Negative gross margin of -3600.0% highlights the cost-intensive nature of developing novel cancer therapies.
• Beta of 1.69 suggests higher volatility compared to the overall market, typical for clinical-stage biotech companies.
• ZIOPHARM employs 103 individuals, reflecting its focus on research and development activities.

Who Are ZIOP's Competitors?

ZIOP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZIOP's Key Strengths?

Innovative Sleeping Beauty and Controlled IL-12 platforms.

• Focus on immuno-oncology, a rapidly growing field.
• Strategic collaborations with leading research institutions.
• Pipeline of product candidates targeting various cancer types.

What Are ZIOP's Weaknesses?

Clinical-stage company with no currently approved products.

• Significant negative profit and gross margins.
• Reliance on successful clinical trial outcomes and regulatory approvals.
• High cash burn rate.

What Could Drive ZIOP Stock Higher?

Clinical data releases for Ad-RTS-hIL-12 plus veledimex in recurrent glioblastoma multiforme throughout 2026.

• Initiation of clinical trials for new T cell receptor + T therapies targeting solid tumors by Q4 2026.
• Continued advancement of chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies.
• Potential for new strategic partnerships and collaborations to expand research capabilities.

What Are the Key Risks for ZIOP?

Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Unsuccessful clinical trial outcomes for key product candidates.
• Regulatory hurdles and delays in obtaining approvals from agencies like the FDA.
• Competition from other immuno-oncology companies developing similar therapies.
• Financial constraints and the need for additional funding to support research and development activities.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for ZIOP?

• Expansion of T cell receptor + T therapies: ZIOPHARM has the opportunity to expand its T cell receptor + T therapies to target a broader range of solid tumors. The solid tumor market represents a significant unmet medical need, with a market size estimated to reach $400 billion by 2030. Successful development and commercialization of these therapies could generate substantial revenue streams for ZIOPHARM.
• Advancement of chimeric antigen receptor + T cell therapies: ZIOPHARM can further advance its chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies. The hematologic malignancy market is projected to grow to $80 billion by 2028. Positive clinical trial results and regulatory approvals in this area could establish ZIOPHARM as a key player in the cell therapy space.
• Development of Ad-RTS-hIL-12 plus veledimex for recurrent glioblastoma multiforme: ZIOPHARM has the potential to develop Ad-RTS-hIL-12 plus veledimex as a treatment for recurrent glioblastoma multiforme in adults. The glioblastoma multiforme market is expected to reach $2 billion by 2027. Successful commercialization of this therapy could provide a significant revenue stream and improve patient outcomes.
• Strategic partnerships and collaborations: ZIOPHARM can pursue additional strategic partnerships and collaborations to expand its research capabilities and access new technologies. Collaborations with academic institutions and other biotechnology companies can accelerate the development of novel immuno-oncology therapies and broaden ZIOPHARM's pipeline.
• Expansion into new geographic markets: ZIOPHARM has the opportunity to expand its operations into new geographic markets, such as Europe and Asia. These markets offer significant growth potential for immuno-oncology therapies, driven by increasing cancer prevalence and rising healthcare expenditures. International expansion could diversify ZIOPHARM's revenue streams and reduce its reliance on the US market.

What Are ZIOP's Competitive Advantages?

• Proprietary Sleeping Beauty platform for genetic engineering of immune cells.
• Controlled IL-12 technology for targeted immune stimulation.
• Patent protection for its key technologies and product candidates.
• Strategic collaborations with leading research institutions.

What Does ZIOP Do?

ZIOPHARM Oncology, Inc., headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing a diverse portfolio of immuno-oncology therapies. The company's primary focus is on treating various forms of cancer by harnessing the power of the patient's own immune system. ZIOPHARM's core technology revolves around two innovative platforms: the Sleeping Beauty platform and Controlled IL-12. The Sleeping Beauty platform facilitates the non-viral genetic engineering of immune cells, specifically T-cells, outside the body. These engineered T-cells are then infused back into the patient to target and destroy cancer cells. The Controlled IL-12 platform is designed to stimulate the expression of interleukin-12 (IL-12), a key regulator of the immune system. By controlling the production of IL-12, the company aims to focus the patient's immune system to specifically attack cancer cells. ZIOPHARM's pipeline includes T cell receptor + T therapies targeting solid tumors, chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies, and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate IL-12 production for recurrent glioblastoma multiforme in adults. The company has established several strategic collaborations, including a license agreement with PGEN Therapeutics, Inc., a research and development agreement with The University of Texas MD Anderson Cancer Center, a patent license agreement with the National Cancer Institute, and a cooperative research and development agreement with the National Cancer Institute. These partnerships enhance ZIOPHARM's research capabilities and expand its access to cutting-edge technologies.

What Products and Services Does ZIOP Offer?

• Develops immuno-oncology therapies to treat cancer.
• Utilizes the Sleeping Beauty platform for non-viral genetic engineering of immune cells.
• Employs Controlled IL-12 technology to stimulate the immune system to attack cancer cells.
• Focuses on T cell receptor + T therapies for solid tumors.
• Develops chimeric antigen receptor + T cell therapies for hematologic malignancies.
• Creates gene delivery systems to regulate IL-12 production for recurrent glioblastoma multiforme.

How Does ZIOP Make Money?

• Develops and patents novel immuno-oncology therapies.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Seeks regulatory approvals from agencies like the FDA.
• Partners with other companies for research, development, and commercialization.

What Industry Does ZIOP Operate In?

ZIOPHARM Oncology, Inc. operates within the rapidly evolving immuno-oncology sector, a segment of the biotechnology industry focused on harnessing the body's immune system to fight cancer. The market is characterized by intense competition, with numerous companies developing novel therapies, including cell therapies, checkpoint inhibitors, and oncolytic viruses. ZIOPHARM's competitive positioning depends on the success of its Sleeping Beauty and Controlled IL-12 platforms in demonstrating superior efficacy and safety compared to existing and emerging therapies.

Who Are ZIOP's Key Customers?

• Cancer patients seeking innovative treatment options.
• Hospitals and oncology clinics.
• Research institutions and universities.
• Pharmaceutical companies through licensing and collaboration agreements.

The most recent 11 insider filings for ZIOPHARM Oncology, Inc. break down as 2 sales and 9 purchases. On net that is roughly 880K shares acquired (about $3.5M) — insiders putting money in tends to read as conviction.

ZIOPHARM Oncology, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 2.8% below estimates on average.

ZIOPHARM Oncology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Key Financial Metrics

Its free cash flow yield is -77.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.77 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -109.9%, the inverse of the P/E and a quick read on earnings relative to price.

ZIOP Revenue & Earnings Trend

In Q2 FY2026, ZIOP generated $0 in top-line revenue. The company recorded a net loss of $952K, with diluted EPS of $-0.39. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, ZIOP averaged $-0.34 in diluted EPS.

Company Profile

ZIOPHARM Oncology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Laurence Cooper. ZIOP has traded publicly since 2004.

ZIOP Financials

ZIOP Latest News

ZIOP Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources